Table of contents:
- Introductory summary
- Definition of severe asthma
- Systematic assessment
- Step 1: Diagnosis and phenotype
- Step 2: Treatment barriers
- Step 3 Exposures and comorbidities
- Management of severe asthma
- Still poor asthma control despite optimised asthma treatment and management?
THE NORDIC SEVERE ASTHMA NETWORK: POCKET GUIDE FOR SYSTEMATIC ASSESSMENT AND MANAGEMENT OF POSSIBLE SEVERE ASTHMA IN ADULTS – 2020
The purpose of this pocket guide is to provide a condensed, practical and pragmatic clinical overview on the assessment and management of possible severe asthma in adults.
The content of this pocket guide is based on the recommendations from the Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults 20181 , where a more detailed description is found.
This Pocket guide is developed by the Nordic Severe Asthma Network (NSAN) established under the Nordic Respiratory Academy (NORA) with severe asthma specialists from Norway, Sweden, Denmark, Iceland, Finland and Estonia as members
Asthma is increasingly recognised as a complex, heterogeneous disease consisting of a variety of clinical, pathophysiological and inflammatory characteristics with an inconsistent and variable response to treatment2–4 . Most patients can achieve well-controlled asthma on low to medium dose of inhaled corticosteroids (ICS). However, a small group of patients remains a major challenge as they persistently require intensive asthma therapy, including high doses of inhaled steroids as well as “second controllers”5–7 . Poor asthma control may, however, be due to several factors. Hence, patients, who are prescribed high-dose asthma treatment, should undergo a thorough systematic assessment in a specialist care setting to confirm the diagnosis of asthma and identify and address potential aggravating comorbidities and environmental triggers, poor adherence to controller medication before being classified as having severe asthma5–8 . The prevalence of severe asthma is estimated to be up to 8 percent of all asthma patients9–12. However, this relatively small proportion of patients with asthma presents the largest burden of disease due to frequent exacerbations, poor quality of life and increased health care costs13,14. Additionally, different targeted, biological therapies are becoming increasingly available for subsets of patients with severe asthma. However, these treatments target very specific pathways in the immune systems and are thus only effective in selected subgroups of severe asthma. Therefore, highlighting the need for a detailed phenotyping of patients with severe asthma.
Definition of severe asthma
The ERS/ATS guidelines5,7 define severe asthma as asthma that remains uncontrolled or where acceptable control is only achieved when receiving high-dose ICS (Table 1) and a second controller (≥ 12 months) or systemic corticosteroids (≥6 months/previous year). The second controllers include long-acting beta-agonists (LABA), leukotriene antagonists (LTRA), long-acting muscarinic antagonists (LAMA) or methylxanthines. The definition excludes patients in whom the poor asthma
control is related to external factors, such as poor adherence or unmanaged comorbidities (difficult-to-treat asthma) (Figure 1). To differentiate these two patient populations, other causes including comorbidities affecting asthma control
should be addressed and managed, including reassessment in specialist care after 3-6 months, before a diagnosis of severe asthma is assigned.
Figure 1: Differentiation of difficult-to-treat versus severe asthma
Several factors including comorbidities and diseases of the upper and lower airways may influence asthma control and mimic severe asthma 5,8. Consequently, a careful stepwise systematic assessment is important to support the diagnosis of
severe asthma5,8,15. There is evidence that after a careful systematic evaluation and management of patients with difficult asthma in a severe asthma centre, less than half can be classified as having severe asthma after 12 months of follow-up16.
The main objective of systematic assessment is to differentiate between severe asthma and difficult-to-treat asthma, the latter being cases in which poor asthma control is mainly caused by external factors (such as poor adherence, untreated
comorbidities and unaddressed triggers).
Overall, systematic evaluation is recommended to include three steps (Figure 2):
1. Confirm the asthma diagnosis, assess asthma control, assess the phenotype
2. Identify and address potential treatment barriers (adherence, poor inhaler technique)
3. Evaluate and manage comorbidities and environmental exposures
Step 1: Diagnosis and phenotype
A. Confirmed asthma diagnosis?
A diagnosis of asthma requires a detailed history including the presence of asthma symptoms combined with objective confirmation of variable airflow limitation (Box 1). Be aware that an inconsistent response to treatment can be due to an
alternative/overlapping diagnosis, especially if non-typical asthma symptoms are dominating or variable airflow limitation is lacking (Table 3). Exclusion of alternative diagnoses:
- Several conditions may mimic severe asthma.
- An alternative or overlapping diagnosis to asthma should always be kept in mind in patients with:
– Inconsistent response to treatment
-Atypical asthma symptoms
-Inability to verify the asthma diagnosis objectively
- Diagnostic work-up according to the clinical suspicion, see Table 3.
- Some conditions co-exist in patients with difficult/severe asthma and are important contributors to asthma symptoms, these are listed in Table 6
Figure 2: Systematic assessment of patients with possible severe asthma (difficult asthma)
B. Level of asthma control
Uncontrolled severe asthma according to the ERS/ATS guidelines5 :
Inadequate symptom control?
o ACQ ≥1.5
o ACT <20
o Uncontrolled according to GINA guidelines6 : frequent symptoms or reliever use, activity limited by wheeze, chest tightness and cough interfere with daily activities, awakenings due to asthma.
≥ 2 OCS requiring exacerbations in the last 12 months≥1 serious exacerbation: hospitalisation, ICU stay or mechanical ventilationAirflow limitation (pre-bronchodilator FEV1 <80 % and FEV1/FVC
C. Clinical phenotype
Overall, there is no clear consensus on the definition of clinical phenotypes for asthma. However, in severe asthma these phenotypes are generally evaluated in clinical practice as follows5:
Early-onset allergic phenotypeLate-onset obese phenotypeLate-onset eosinophilic phenotypeFrom a pragmatic clinical point of view the following features should be systematically described.
Early/late onset asthma? (Onset of asthma symptoms in childhood or in adulthood)
Evidence of Type 2 (T2) inflammation:
- Evidence of eosinophilic airway inflammation (current and/or historical):
- Blood eosinophil count ≥0.3 x109 cells/L19,20
- Sputum eosinophil count ≥3% (only available in some specialised asthma centres)21
- FeNO >25 ppb*22
In patients with no evidence of eosinophilic airway inflammation, consider repeating blood eosinophilic count and FeNO several times, and if possible perform induced sputum or consider bronchoscopy with cell counts in BAL before assuming
*FeNO >50 ppb indicates high likelihood of eosinophilic airway inflammation. Whereas, FeNO <25 indicates low likelihood of eosinophilia22.
- IgE mediated allergy?
- Positive skin prick test, elevated specific IgE (>0.35 kU/L) for aeroallergens with relevant symptoms? 23
- Fixed airflow obstruction (FEV1<80% and FEV1/FVC <0.7)?Obesity (BMI >30kg/m2 )
- Smoking history?
Step 2: Treatment barriers
Identification of factors that impede the delivery of asthma medication to the airways, including nonadherence to treatment and incorrect inhaler technique, is crucial. A diagnosis of severe asthma presupposes that medication is taken as
prescribed, but non-adherence is unfortunately common, even in patients on highdose treatment5,8. If adherence is not systematically evaluated in patients with poor symptom control despite high dose treatment, non-adherent patients are
likely to be misclassified as having severe asthma. This potentially leads to an inappropriate intensification of treatment including commencement of OCS (with the risk of systemic side-effects24) or expensive biological therapies25–27.
- Poor adherence to ICS in patients with difficult asthma is common (40-65 %)28–30 and is related to poor asthma outcomes including higher use of SABA, poor quality of life, lower FEV1, exacerbations and asthma related hospital admissions29,31.
Consequently, we recommend that adherence be routinely assessed
- There is no clear consensus on the cut-off describing non-adherence. However, if using electronic registries for prescription fillings, patients are often considered adherent if ≥80% of ICS prescriptions are filled9,28,30,32
- See Table 4 for more details
B. Inhaler technique:
- Poor inhaler technique in patients with difficult asthma is common (20-60 %)9,28,30 and leads to poor asthma control and increased risk of exacerbations33. It is a particular challenge that these patients often have multiple inhalers each
requiring different techniques to ensure correct administration. Consequently, we recommend inhaler technique to be thoroughly taught and checked at each new prescription, and systematically evaluated during each visit to the outpatient
clinic. At every visit to the outpatient clinic, patients should demonstrate inhaler technique. Thus, ensuring that critical errors are systematically identified and corrected.
- More details are listed in Table 4
C. Self-management skills:
- Patients need a minimum set of skills to manage their disease adequately and optimise asthma control. Asthma patients need a basic understanding of their disease. This includes knowledge of triggers and comorbidities. They need to understand how their different medications work and their respective side effects. Additionally they need to be able to recognize the advent of exacerbations and how to handle them34. Asthma education and guidance have shown to improve quality
of life and reduce hospital admissions.
- Written action plans: guidance on maintenance therapy, recognition and management of exacerbations.
- Self-management education by specialised asthma nurses The identification and management strategies of treatment barriers are shown in Table 4.
Step 3 Exposures and comorbidities
Identification of comorbidities and exposures are central to the systematic evaluation of patients with possible severe asthma.
A. Exposures and modifiable risk factors
Asthma symptoms can be aggravated by several external triggers or irritants including allergens, smoking, pollution and certain drugs6,37. Assessment requires a detailed history including smoking history, exposure to different allergens,
drugs and occupational exposure and is listed in Table 5.
B. Evaluation and management of comorbidities in severe asthma
Comorbidities in patients with difficult or severe asthma are common12,16,28,38,39. Some comorbidities can mimic asthma symptoms and others are associated with poor asthma outcomes38,40. Consequently, by identifying and managing comorbidities,
potential overtreatment of asthma may be avoided and a correct diagnosis of severe asthma ensured39, 41. The most common and important comorbidities and their respective symptoms, diagnostic tests and management are listed in Table 6.
A detailed description of comorbidities in severe asthma is available in the original “Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults” 1 .
Management of severe asthma
Overall, the management of severe asthma can be divided into three domains as shown in Figure 3: Nonpharmacological management, pharmacological treatments and management of comorbidities.
Figure 3: Treatment strategies for severe asthma:
The principles of asthma treatment presented in this guide are mostly based on the 2019 GINA guidelines6 with some modifications (Figure 4). We propose a stepwise approach according to the inflammatory phenotype when managing severe asthma (Figure 5).
Figure 4: Treatment steps according to GINA 2019/6
Figure 5: Stepwise therapeutic approach in patients with severe uncontrolled asthma
Optimising step 5 treatment
Patients with severe asthma are per definition treated with high-dose ICS and a second controller. Before considering biological treatments, regular asthma therapy should be optimized. Potential contributing factors must be addressed and
managed, such as external triggers, comorbidities and treatment barriers.
- Consider optimising inhalers: from metered-dose inhalers (pMDI) to dry powder inhalers (DPI) or vice versa according to patients/treating specialists preference, consider spacers if using pMDI
- Consider additional controllers as add-on treatments:
- LAMA: especially in patients with exacerbations 64,65
- LTRA: consider in patients with AERD or allergic rhinitis6
- Consider reliever treatments: as needed ICS-formoterol is preferred in patients with exacerbations66
- In patients, who are not well-controlled on high dose ICS-LABA, consider referral to a severe asthma specialist/centre1,5
Still poor asthma control despite optimised asthma treatment and management?
Further treatment opportunities according to the inflammatory phenotype (Figure 5):
Evidence of T2 inflammation:
- Reconsider adherence!
- Consider increasing ICS6 – be aware of side effects!
- Consider low-dose macrolides:
- Conflicting results, however there is some evidence that treatment with azithromycin 250-500 mg three times a week reduces exacerbations in patients with eosinophilic as well as noneosinophilic airway inflammation67,68
- Be aware of: prolonged QTc, hearing loss/tinnitus and potential bacterial resistance67
- Consider low dose OCS:
- Low evidence, therefore the lowest dose for as short time as possible.
- Be aware of side-effects: diabetes, hypertension, peptic ulcers, osteoporosis24,69,70
- Consider ABPA: Specific IgE/IgG against Aspergillus fumigatus, total IgE, blood eosinophils, bronchiectasis (HRCT)71
- Consider biological therapies (according to eosinophilic or allergic predominance):
- Allergic asthma:
- Perennial atopy combined with allergen induced symptoms+ exacerbations + total IgE within dose range* 72–74
- Reduces exacerbations, improves symptom control and lung function72,75,76
- Predictors of treatment response: see Figure 6
- Eosinophilic asthma:
- Exacerbations + blood eosinophil count ≥ 0.3 x 109 /L (lower if patients on long-term OCS)*6,19
- Reduces exacerbations19,77,78
- Less effect on symptoms and lung function78–80.
- OCS sparing effect81,82
- Effect on chronic rhinosinusitis with nasal polyps83
- Predictors of treatment response: see Figure 6
- Exacerbations + blood eosinophil count ≥ 0.15 x 109 / FeNO≥25 ppb (lower if patients are on long-term OCS)* 6,84
- Reduces exacerbations, increases lung function and symptom control 84
- Allergic asthma:
• OCS sparing effect 85
• Effect on chronic rhinosinusitis with nasal polyps 86 and atopic dermatitis 87
• Predictors of treatment response: See Figure 6
*Check local eligibility criteria for the different biological treatments, as these may vary from those listed.
At present, no direct comparisons between any of the biological therapies exist.
T2 low inflammation
- Reconsider important comorbidities/alternative diagnosis: e.g. VCD, DB, COPD, bronchiectasis, obesity etc. (Table 3, Table 6): consider HRCT, lung volumes, DLCO, induced sputum if not done
- Add LAMA if not yet in use (especially if FEV1 <80% and exacerbations)
- Consider low-dose macrolides:
o Conflicting results, however there is some evidence that treatment with azithromycin 250-500 mg three times a week reduces exacerbations in patients with non-eosinophilic as well as eosinophilic airway inflammation67,68
o Be aware of: prolonged QTc, hearing loss/tinnitus and potential bacterial resistance (sputum cultures should be obtained if bronchiectasis is present)67
- Consider bronchial thermoplasty
o Reduces long-term exacerbations, but is associated with increased risk of exacerbations in relation to the procedure 88
o Contraindications: bronchiectasis, FEV1<50%
o Lack of long-term follow up data 5
Figure 6: Predictors of treatment response to anti-IgE, anti-IL5/IL5R and anti IL4/13:
Minimum assessment before commencing a biological drug
Patients with difficult asthma should undergo a detailed systematic assessment according to the three evaluation steps described earlier in this document (Figure 2)
1. Diagnosis & phenotype
2. Identification of treatment barriers
3. Identification and management of exposures and comorbidities
Before commencing a biological drug, we advocate that at minimum the following to be evaluated and managed including reviewing response to management after approximately 3-6 months to ensure a true diagnosis of severe refractory asthma,
as illustrated in Figure 7.
Figure 7: Recommended minimum assessment before commencing T2-targeted biological therapies for severe asthma.
Referral to a severe asthma centre:
Consider referral if:
- Difficult and persistent uncontrolled asthma (low lung function, poor symptom control or frequent exacerbations) on GINA step 5 treatments (high dose ICS + second controller) despite good adherence, correct inhaler therapy and attempts
to optimise therapy with different inhalers and addon therapies
- Treatment with maintenance OCS
Content in referral letter to a severe asthma centre is illustrated in Box 2
ABPA: Allergic bronchopulmonary aspergillosis
ACE: Angiotensin-converting enzyme
ACT: Asthma Control Test
ACQ: Asthma Control Questionnaire
AHR: Airway hyperresponsiveness
ASA: acetylsalicylic acid
ATS: American Thoracic Society
COPD: Chronic obstructive pulmonary disease
CPAP: Continuous Positive Airway Pressure
CT: Computed tomography
DB: Dysfunctional breathing
DLCO: Diffusing capacity for carbon monoxide
DPI: Dry powder inhaler
ERS: European Respiratory Society
FEV1: Forced expiratory volume in 1 second
FVC: Forced vital capacity
FeNO: Fractional exhaled nitric oxide
GERD: Gastroesophageal reflux disease
GINA: Global Initiative for Asthma
GSRS: Gastrointestinal Symptom Rating Scale
HADS: Hospital Anxiety and Depression Scale
HRCT: High resolution computed tomography
ICS: Inhaled corticosteroids
ILO: Inducible laryngeal obstruction
LABA: Long-acting beta-agonist
LAMA: Long-acting muscarinic antagonist
LTRA: Leukotriene antagonist
MDI: Metered-dose Inhaler
NSAID: Nonsteroidal anti-inflammatory drug
NSAN: Nordic Severe Asthma Network
NORA: Nordic Respiratory Academy
OCS: Oral corticosteroids
OSAS: Obstructive sleep apnea syndrome
PEF: Peak expiratory flow
SABA: Short-acting beta-agonist
1: Porsbjerg C, Ulrik C, Skjold T, Backer V, Laerum B, Lehman S et al. Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. Eur Clin Respir J 2018; 5: doi: 10.1080/20018525.2018.1440868.
2: Haldar P, Brightling CE, Berverley H, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. N Engl J Med 2009; 360: 973–984.
3: Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X et al. Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323.
4: Wenzel SE. Asthma : defining of the persistent adult phenotypes. Lancet 2006; 368: 804–13.
5: Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
6: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2019. available http://www.ginasthma.org, Date last Updat 2019 Last accessed Sep 1 2019.
7: Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Gaga M et al. Early View Task Force Report Management of Severe Asthma : a European Respiratory Society / American Thoracic Society Guideline Management of Severe Asthma : a European
Respiratory Society / American Thoracic Society Guideline. Eur Respir J 2019; in press: https://doi.org/10.1183/13993003.00588-2019.
8: Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66: 910–917.
9: Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135: 896–902.
10: von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among danish adults. J Allergy Clin Immunol Pr 2014; 2: 759–767.
11: Backman H, Jansson S-A, Stridsman C, Eriksson B, Hedman L, Eklund B-M et al. Severe asthma — A population study perspective. Clin Exp Allergy 2019; 49: 819–828.
12: Ilmarinen P, Tuomisto LE, Niemel O, Kankaanranta H. Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma. J Allergy Clin Immunol Pract 2019; 7: 165-174.e4.
13: Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L et al. Characterization of the severe asthma phenotype by the National Heart, Lung and Blood Institute’s Severe Asthma Research Program. J allergy Clin Immunol
2007; 119: 405–413.
14: O’Neill S, Sweeney J, Patterson CC, Menzies-gow A, Niven R, Mansur AH et al. The cost of treating severe refractory asthma in the UK : an economic analysis from the British Thoracic Society Dif fi cult Asthma Registry. Thorax 2015; 70:
15: Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet L-P et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119: 1337–48.
16: Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003; 58: 561–6.
17: Coates AL, Wanger J, Cockcroft DW, Culver BH, Carlsen K-H, Diamant Z et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49: 1–17.
18: Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K et al. A new method for bronchialprovocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156: 758–765.
19: Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma ( DREAM ): a multicentre , double-blind , placebo-controlled trial. Lancet 2012; 380: 651–659.
20: Fowler SJ, Tavernier G, Niven R. High blood eosinophil count predict sputum eosinophlia in patients with severe asthma. J allergy Clin Immunol 2015; 135: 822–4.e2.
21: Simpson JL, Mcelduff P, Gibson PG. Assessment and Reproducibility of Non-Eosinophilic Asthma Using Induced Sputum. Respiration 2010; 79: 147–151.
22: Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO et al. An Official ATS Clinical Practice Guideline : Interpretation of Exhaled Nitric Oxide Levels ( FeNO ) for Clinical Applications. Am J Respir Crit Care Med 2011; 184:
23: ARIA ( Allergic Rhinitis and its Impact on Asthma ) 2008 Update. available http://www.whiar.org, Date last Updat 2016, accessed June 1 2019.
24: Ekström M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use , morbidity and mortality in asthma : A nationwide prospective cohort study in Sweden. Allergy 2019; 74: 2181–2190.
25: Lindsay JT, Heaney LG. Nonadherence in difficult asthma – facts, myths, and a time to act. Patient Prefer Adherence 2013; 7: 329–36.
26: Bårnes CB, Ulrik CS. Asthma and Adherence to Inhaled Corticosteroids : Current Status and Future Perspectives. Respir Care 2015; 60: 455–468.
27: Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax 2012; 67: 268–270.
28: von Bülow A, Backer V, Bodtger U, Soes-Petersen NU, Vest S, Steffensen I et al. Differentiation of adult severe asthma from difficult-to-treat asthma – Outcomes of a systematic assessment protocol. Respir Med 2018; 145: 41–47.
29: Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012; 67: 751–3.
30: Meer A Van Der, Pasma H, Kempenaar-okkema W, Pelinck J-A, Schutten M, Storm H et al. A 1-day visit in a severe asthma centre : effect on asthma control , quality of life and healthcare use. Eur Respir J 2016; 48: 726–733.
31: Gamble J, Stevenson M, Mcclean E, Heaney LG. The Prevalence of Nonadherence in Difficult Asthma. Am J Respir Crit Care Med 2009; 180: 817–822. 24
32: Mcnicholl DM, Stevenson M, Mcgarvey LP, Heaney LG. The Utility of Fractional Exhaled Nitric Oxide Suppression in the Identification of Nonadherence in Difficult Asthma. Am J Respir Crit Care Med 2012; 186: 1102–1108.
33: Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930–938.
34: McDonald VM, Vertigan AE, Gibson PG. How to set up a severe asthma service. Respirology 2011; 16: 900–11.
35: Foster JM, Smith L, Bosnic-Anticevich SZ, Usherwood T, Sawyer SM, Rand CS et al. Identifying patientspecific beliefs and behaviours for conversations about adherence in asthma. Intern Med J 2012; 42: e136-44.
36: Braido F, Baiardini I, Blasi F, Pawankar R. Adherence to asthma treatments : ‘we know, we intend, we advocate’. Curr opin Allergy Clin Immunol 2015; 15: 49–55.
37: McCracken JL, Sreenivas PV, Ameredes BT, Calhoun WJ. Diagnosis and Management of Asthma in Adults A Review. JAMA 2017; 318: 279–290.
38: ten Brinke A, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt JT, Zwinderman AH et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26: 812–818.
39: Tay TR, Lee J, Radhakrishna N, Hore-Lacy F, Stirling R, Hoy R et al. A Structured Approach to Specialistreferred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes. J Allergy Clin Immunol Pract 2017;
40: Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Dabscheck E et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology 2016; 21: 1384–1390.
41: Porsbjerg CM, Menzies-Gow A. Co-morbidities in severe asthma: Clinical impact and management. Respirology 2017; 22: 651–661.
42: Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C et al. ScienceDirect Heterogeneity of phenotypes in severe asthmatics . The Belgian Severe Asthma Registry ( BSAR ). Respir Med 2014; 108: 1723–1732.
43: Rosenfeld R, Andes D, Bharracharyya N, Cheung D, Eisenberg S, Ganiats T et al. Clinical practice guideline: Adult sinusitis. Otolaryngol – Head Neck Surg 2007; 137: S1–S31.
44: Gibson PG, Mcdonald VM. Asthma – COPD overlap 2015 : now we are six. 2015; : 683–691.
45: Boulding R, Stacey R, Niven R, Fowler SJ. Dysfunctional breathing : a review of the literature and proposal for classification. Eur Respir J 2016; 25: 287–294.
46: van Dixhoorn J, Duivenvoorden H. Efficacy of Nijmegen questionnaire in recognition of the hyperventilation syndrome. J Psycosomatic Res 1985; 29: 199–206.
47: Todd S, Walsted ES, Grillo L, Livingston R, Menzies-Gow A, Hull JH. Novel assessment tool to detect breathing pattern disorder in patients with refractory asthma. Respirology 2017; : doi: 10.1111/resp.13173.
48: Denton E, Bondarenko J, O’Hehir R, Hew M. Breathing pattern disorder in difficult asthma : Characteristics and improvement in asthma control and quality of life after breathing re-training. 25 Allergy 2018; : DOI: 10.1111/all.13611.
49: Low K, Lau KK, Holmes P, Crossett M, Vallance N, Phyland D et al. Abnormal Vocal Cord Function in Difficult-to-Treat Asthma. Am J Respir Crit Care Med 2011; 184: 50–56.
50: Hull J, Walsted ES, Pavitt M, Menzies-gow A, Backer V, Sandhu G. High Prevalence of Laryngeal Obstruction during Exercise in Severe Asthma. Am J Respir Crit Care Med 2019; 199: 538–542.
51: Traister RS, Fajt ML, Landsittel D, Petrov AA. A Novel Scoring System to Distinguish Vocal Cord Dysfunction From Asthma. J Allergy Clin Immunol Pract 2014; 2: 65–69.
52: Haldar P, Pavord ID, Shaw DE, Berry M a, Thomas M, Brightling CE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–24.
53: Teodorescu M, Broytman O, Curran-Everett D, Sorkness RL, Crisafi G, Bleecker ER et al. Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway Inflammation in Adults in the Severe Asthma Research Program (SARP) II. J Allergy Clin
Immunol Pract 2015; 3: 566-575.e1.
54: Owens ROL, Macrea MAM, Teodorescu MI. The overlaps of asthma or COPD with OSA : A focused review. Respirology 2017; 22: 1073–1083.
55: Netzer NC, Stoohs RA, Netzer CM, Clark K, Sthrohl KP. Using the Berlin Questionnaire to Identify Patients at Risk for the Sleep Apnea Syndrome. Ann Intern Med 1999; 131: 485–491.
56: Kendzerska TB, Smith PM, Brignardello-petersen R, Leung RS, Tomlinson GA. Evaluation of the measurement properties of the Epworth sleepiness scale : A systematic review. Sleep Med Rev 2014; 18: 321–331.
57: Scott HA, Gibson PG, Garg ML, Pretto JJ, Morgan PJ, Callister R et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma : a randomized trial. Clin Exp Allergy 2013; 43:
58: Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015; 46: 1308– 1321.
59: Gibson P, Henry R, Coughlan J. Gastro-oesophageal reflux treatment for asthma in adults and children ( Review ). Cochrane Database Syst Rev 2003; : DOI: 10.1002/14651858.CD001496.
60: Bisaccioni C, Aun MV, Cajuela E, Kalil J, Agondi RC, Giavina-Bianchi P. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clinics 2009;
61: Gupta S, Siddiqui S, Haldar P, Raj JV, Entwisle JJ, Wardlaw AJ et al. Qualitative Analysis of HighResolution CT Scans in Severe Asthma. Chest 2009; 136: 1521–1528.
62: Polverino E, Goeminne PC, Mcdonnell MJ, Aliberti S, Marshall SE, Loebinger MR et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629 [https://doi.org/ 10.1183/13993003.00629–2.
63: Greenberger P a., Bush RK, Demain JG, Luong A, Slavin RG, Knutsen AP. Allergic Bronchopulmonary Aspergillosis. J Allergy Clin Immunol Pract 2014; 2: 703–708.
64: Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M et al. Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. N Engl J Med 2012; 367: 1198–1207. 26
65: Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway
obstruction, and allergic status. Respir Med 2016; 117: 198–206.
66: O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129–36.
67: Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled
trial. Lancet 2017; 390: 659–668.
68: Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68:
69: Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US Costs of CorticosteroidAssociated Adverse Events : A Systematic Literature Review. Clin Ther 2011; 33: 1413–1432.
70: Manson SC, Brown RE, Cerulli A, Fernandez C. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009; 103: 975–994.
71: Greenberger PA, Bush RK, Demain JG, Luong A, Slavin RG, Knutsen AP. Allergic Bronchopulmonary Aspergillosis. J Allergy Clin Immunol Pr 2014; 2: 703–708.
72: Hanania NA, Alpan O, Hamilos D, Condemi J, Reyes-Rivera I, Zhu J et al. Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy. Ann Intern Med 2011; 154: 573–582.
73: Hanania NA, Wenzel S, Rosen K, Hsieh H, Mosesova S, Choy DF et al. Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study. Am J Respir Crit Care Med 2013; 187: 804–811.
74: Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care. J Allergy Clin Immunol 2015; 135. doi:10.1016/j.jaci.2014.12.1871.
75: Macdonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma : systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol
2019; 15: 553–569.
76: Humbert M, Beasley R, Ayres J, Slavin R, Bousquet J, Ramos S et al. Original article Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (
GINA 2002 step 4 treatment ): INNOVATE. Allergy 2005; 60: 309–316.
77: Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts : results from two multicentre , parallel , double-blind , randomised ,
placebo-controlled , phase 3 trials. Lancet Respir Med 2015; 3: 355–366.
78: Bleecker ER, Fitzgerald JM, Chanez P, Papi A, Weinstein SF, Barker P et al. Effi cacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β 2 -agonists ( SIROCCO
): a randomised , multicentre , placebo-controlled phase 3 trial. Lancet 2016; 29: 2115–2127. 27
79: Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels. Chest 2016; 150: 789–798.
80: Ortega HG, Liu MC, Pavord ID, Brusselle GG, Fitzgerald JM, Chetta A et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med 2014; 371: 1198–1207.
81: Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. Nejm 2014; 371. doi:10.1056/NEJMoa1403291.
82: Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo N, Kuna P et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med 2017; 376: 2448–58.
83: Rivero A, Liang J. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis : A Systematic Review and Meta-analysis. Ann Otol Rhinol Laryngol 2017; : DOI: 10.1177/0003489417731782.
84: Castro M, Corren J, Pavord I., Maspero J, Wenzel S, Rabe KF et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 2018. doi:10.1056/NEJMoa1804092.
85: Rabe KF, Parameswaran N, Bruselle G, Maspero JF, Castro M, Sher L et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 2019; 378: 2475–2485.
86: Bachert C, Hellings PW, Mullol J, Naclerio RM, Chao J, Amin N et al. Dupilumab improves patientreported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract 2019; in press.
87: Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. N Engl J Med 2019; 371: 130–139.
88: Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial.
Am J Respir Crit Care Med 2010; 181: 116–24.
89: Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ et al. Clinical Guidelines for the Use of Unattended Portable Monitors in the Diagnosis of Obstructive Sleep Apnea in Adult Patients. J Clin Sleep Med 1997; 3: 737–747.
90: Postma DS, Rabe KF. The Asthma–COPD Overlap Syndrome. N Engl J Med 2015; 373: 1–4